St. Jude Children's Research Hospital

The United States of America, as Represented by the Secretary, Department of Health and Human Services

The University of Tennessee Research Foundation

Sequella, Inc.

Other

Coa Therapeutics, Inc.

The University of Texas System

Washington University

George Mason University

Richard Edward Lee

Ying Zhao

Jiuyu Liu

Marina Nikolaevna Protopopova

Clifton E Barry, Iii

Richard Allan Slayden

Julian G Hurdle

Zhong Zheng

Leo Einck

Elena Bogatcheva

Charles O Rock

Liu Jiuyu

Chitra Subramanian

Suzanne Jackowski

Mi Kyung Yun

Robert J Zamboni

T Jagadeeswar Reddy

Rajendra P Tangallapally

Lalit Kumar Sharma

Anne V Edwards

Elizabeth Griffith

Jianjun Qi

Aman P Singh

Bernd Meibohm

Vnr Pavan Kumar Vaddady

Rakesh

Cynthia Dowd

Jason W Rosch

Kylene Wesley Kehn-Hall

Philip T Cherian

Xiaoqian Wu

Shirley Lee

Helena I Boshoff

Emily R Jackson

Robin Lee

Geraldine San Jose

Samanthi L Waidyarachchi

David F Bruhn

Raghunandan Yendapally

Pavan Vaddady

Clifton E Barry

Rakesh,

Pavan Kumar Vaddady

Clifton E Barry Iii

The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Small molecule modulators of pantothenate kinases

The present disclosure relates to methods of treating a coenzyme A reduction, elevation, sequestration, toxicity, or redistribution (CASTOR) disease such as, for example, defects in fatty acid oxidation enzymes, methylmalonic acidemia, glutaric acidemia, propionic academia, and HMG-CoA lyase, via small molecule modulators of CoA levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Methods of treating disorders associated with castor

In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the ClpP endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Substituted urea depsipeptide analogs as activators of the ClpP endopeptidase

In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the C1pP endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Substituted urea depsipeptide analogs as activators of the CLPP endopeptidase

The invention relates to aryl substituted aminomethyl spectinomycin analogs, derivatives thereof, and related compounds, which are useful as anti-bacterial agents; methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating anti-bacterial infections using the compounds and compositions.

Aryl substituted aminomethyl spectinomycin analogs as antibacterial agents

In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators with the ClpP endopeptidase; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of search in the particular art and is not intended to be limiting of the present invention.

Compounds for the treatment of bacterial and parasitic infections which are hybrid compounds of compounds having antibacterial or antiparasitic activity and compounds that decrease the absorption of the hybrid compound from the gastrointestinal tract. The compounds are preferably for use againstinfections and comprise a hybrid molecule of an anti-compound such as a nitroimidazole and a tetramic acid derivative.

Treatments for gastrointestinal conditions

In particular, the compound is effective to inhibit Dxr in(Mtb). The present invention relates to compounds having general formula (I) or (II) 

Compounds for inhibiting 1-deoxy-D-xylulose-5-phosphate reductoisomerase

Novel 3'-deoxy-3&#x2032;-acylaminospectinomycin compounds are described. Also described are methods of using the 3&#x2032;-deoxy-3-acylaminospectinomycin compounds and other spectinomycin analogs in treating tuberculosis and in treating microbial infections.

Spectinamides as anti-tuberculosis agents

Tetramic acid analogues of Formula I and Formula II have antibacterial activity, primarily against gram-positive bacteria, and are iron chelators.

Analogs of tetramic acid

Growing community of inventors

Cordova, TN, United States of America

Richard Edward Lee